Can you take Guaifen PE with Solriamfetol?

Solriamfetol has a moderate potential interaction with Anxiety and Stress.

The use of solriamfetol may cause adverse psychiatric reactions, including anxiety, insomnia, and irritability. It is recommended to exercise caution when treating patients who have a history of psychosis or bipolar disorders. Observe patients treated with solriamfetol for the possible emergence or exacerbation of psychiatric symptoms and consider dose reduction or discontinuation of treatment.

The phenylephrine in Guaifen PE has a moderate potential interaction with Benign Prostatic Hyperplasia.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

The phenylephrine in Guaifen PE has a major potential interaction with Cardiovascular Conditions and Disorders.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Solriamfetol has a moderate potential interaction with Cardiovascular Conditions and Disorders.

The primary route of solriamfetol elimination is via urinary excretion. Dosage adjustment is not required for patients with mild renal impairment. Dosage adjustment is recommended for patients with moderate to severe renal impairment. Solriamfetol is not recommended for patients with end-stage renal disease. An average of 21% of solriamfetol is removed by hemodialysis. Patients with moderate or severe renal impairment may be at a higher risk of increases in cardiovascular adverse events and psychiatric symptoms because of the prolonged half-life.

Solriamfetol has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Solriamfetol increases systolic blood pressure, diastolic blood pressure, and heart rate in a dose-dependent fashion. It is recommended to exercise caution when treating patients at higher risk of cardiovascular toxicities, particularly patients with known cardiovascular and cerebrovascular disease, preexisting hypertension, and patients with advanced age. Assess blood pressure and control hypertension before initiating treatment and monitor blood pressure regularly during treatment. Periodically reassess the need for continued therapy with solriamfetol and treat new-onset hypertension and exacerbations of preexisting hypertension according to clinical guidelines. If a patient experiences increases in blood pressure or heart rate that cannot be managed with dose reduction or other appropriate medical intervention, consider treatment discontinuation.

The phenylephrine in Guaifen PE has a major potential interaction with Cerebrovascular Insufficiency.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

The phenylephrine in Guaifen PE has a moderate potential interaction with Diabetes Mellitus.

Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.

The phenylephrine in Guaifen PE has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Sympathomimetic agents can induce transient mydriasis via stimulation of alpha-1 adrenergic receptors. In patients with anatomically narrow angles or narrow-angle glaucoma, pupillary dilation can provoke an acute attack. In patients with other forms of glaucoma, mydriasis may occasionally increase intraocular pressure. Therapy with sympathomimetic agents should be administered cautiously in patients with or predisposed to glaucoma, particularly narrow-angle glaucoma.

Solriamfetol has a moderate potential interaction with Heart Disease.

Solriamfetol increases systolic blood pressure, diastolic blood pressure, and heart rate in a dose-dependent fashion. It is recommended to exercise caution when treating patients at higher risk of cardiovascular toxicities, particularly patients with known cardiovascular and cerebrovascular disease, preexisting hypertension, and patients with advanced age. Assess blood pressure and control hypertension before initiating treatment and monitor blood pressure regularly during treatment. Periodically reassess the need for continued therapy with solriamfetol and treat new-onset hypertension and exacerbations of preexisting hypertension according to clinical guidelines. If a patient experiences increases in blood pressure or heart rate that cannot be managed with dose reduction or other appropriate medical intervention, consider treatment discontinuation.

The phenylephrine in Guaifen PE has a major potential interaction with Hyperthyroidism.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

The phenylephrine in Guaifen PE has a major potential interaction with Pheochromocytoma.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

The phenylephrine in Guaifen PE has a moderate potential interaction with Prostate Tumor, Benign.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

Solriamfetol has a moderate potential interaction with Psychosis.

The primary route of solriamfetol elimination is via urinary excretion. Dosage adjustment is not required for patients with mild renal impairment. Dosage adjustment is recommended for patients with moderate to severe renal impairment. Solriamfetol is not recommended for patients with end-stage renal disease. An average of 21% of solriamfetol is removed by hemodialysis. Patients with moderate or severe renal impairment may be at a higher risk of increases in cardiovascular adverse events and psychiatric symptoms because of the prolonged half-life.

Solriamfetol has a moderate potential interaction with Psychosis.

The use of solriamfetol may cause adverse psychiatric reactions, including anxiety, insomnia, and irritability. It is recommended to exercise caution when treating patients who have a history of psychosis or bipolar disorders. Observe patients treated with solriamfetol for the possible emergence or exacerbation of psychiatric symptoms and consider dose reduction or discontinuation of treatment.

Solriamfetol has a moderate potential interaction with Renal Dysfunction.

The primary route of solriamfetol elimination is via urinary excretion. Dosage adjustment is not required for patients with mild renal impairment. Dosage adjustment is recommended for patients with moderate to severe renal impairment. Solriamfetol is not recommended for patients with end-stage renal disease. An average of 21% of solriamfetol is removed by hemodialysis. Patients with moderate or severe renal impairment may be at a higher risk of increases in cardiovascular adverse events and psychiatric symptoms because of the prolonged half-life.